Last reviewed · How we verify
Cycle 8 Reinduction
At a glance
| Generic name | Cycle 8 Reinduction |
|---|---|
| Also known as | VCR + IDR + DXM + PDN + CY + IT |
| Sponsor | Gruppo Italiano Malattie EMatologiche dell'Adulto |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Comparing Cytarabine + Daunorubicin Therapy Versus Cytarabine + Daunorubicin + Venetoclax Versus Venetoclax + Azacitidine in Younger Patients With Intermediate Risk AML (A MyeloMATCH Treatment Trial) (PHASE2)
- MYELOMATCH: A Screening Study to Assign People With Myeloid Cancer to a Treatment Study or Standard of Care Treatment Within myeloMATCH (MyeloMATCH Screening Trial) (PHASE2)
- Revumenib in Combination With 7+3 + Midostaurin in AML (PHASE1)
- LBL-2016 for Children or Adolescents in China (PHASE3)
- Ponatinib Plus Chemotherapy in Acute Lymphoblastic Leukemia Patients (PHASE2)
- Trial of DFP-10917 vs Non-Intensive or Intensive Reinduction for AML Patients in 2nd/3rd/4th Salvage (PHASE3)
- Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma (PHASE2, PHASE3)
- Pooled Mutant KRAS-Targeted Long Peptide Vaccine Combined With Nivolumab and Ipilimumab for Patients With Resected Mismatch Repair Protein (MMR-p) Colorectal and Pancreatic Cancer (PHASE1)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |